tbuckley/cabot-search huggingface dataset:
韦格纳肉芽肿病合并肺部烟曲霉菌感染一例
Authors: 李昕, 张娜, 巩路
Journal: BMJ (2009)

韦格纳肉芽肿病是一种病因未明的坏死性肉芽肿性血管炎,临床表现多样[1].由于早期诊断和治疗方法的改进,患者生存率有了明显提高,而条件致病菌感染成为该病苇要的死因.常见病原微生物包括卡氏肺囊虫、水痘一带状疱疹病毒以及念珠菌属等[2]。
内分泌科临床精粹(二)
Authors: 李乃适, 连小兰
Journal: BMJ (2010)

一、临床有高代谢症状,血清甲状腺激素水平升高而促甲状腺激素(TSH)正常即需怀疑TSH瘤的可能下丘脑-垂体-甲状腺轴的生理调节是非常精确的,当血清甲状腺激素水平升高时,血清TSH将迅速被抑制.因此,如果血清甲状腺激素水平升高而TSH未能被抑制,而临床又有高代谢症状时,则需要高度怀疑TSH自主分泌增多导致甲状腺功能亢进(甲亢),查鞍区MRI常常可发现垂体瘤表现.如果按照一般Graves病的处理原则使用抗甲状腺药物处理的话,则可能会促进TSH瘤的生长.原则上TSH瘤首选术前用奥曲肽准备后手术治疗。
Successful diagnosis and treatment of poisoning induced by Datura seedlings
Authors: Zhang Jinqiao
Journal: BMJ (2016)

食用曼陀罗植物导致的中毒临床少见。报道一起误食曼陀罗幼苗致急性中毒5例患者的诊治过程，提示基层医生遇到以副交感神经功能阻断症状及中枢神经兴奋症状的类阿托品中毒症状入院的急性食物中毒，应高度怀疑曼陀罗生物碱中毒，及时采取特异解毒和对症治疗，可提高救治成功率。
Combination of fulvestrant and chemotherapy in ESR1 Y537S mutant breast cancer cells and potential synergy mechanism related to p53 wildtype.
Authors: Wen Ma, Francisco Hermida-Prado, Cristina Guarducci, Avery Feit, Agostina Nardone, Gabriella Cohen, Wenting Pan, Hongliang Wei, Nanlin Li, Myles Brown, Rinath Jeseslsohn
Journal: Journal of Clinical Oncology (2020)

1065 Background: The acquisition of ligand-independent ESR1 mutations during endocrine therapy in metastatic ER+ breast cancer is a common mechanism of resistance to endocrine treatment, particularly aromatase inhibitors, and found in more than 30% of patients with metastatic ER+ breast cancer. Our recent work showed that the ER mutations confer resistance to currently available endocrine treatments while promoting an aberrant ER transcriptional activity that drives metastases. These results underscore the importance of targeting the ESR1 mutations even after the development of endocrine resistance. We hypothesized that during chemotherapy treatment, the ESR1 mutations remain an important driver of tumor growth and metastases and therefore drugs targeting the ESR1 mutation could enhance the efficacy of chemotherapy. In this study we investigated the combination of chemotherapy with the selective estrogen receptor degrader in the presence of WT and mutant ER. Methods: We performed synergy studies testing the combination of fulvestrant with chemotherapy treatments commonly used in ER+ metastatic breast cancer including 5FU (representing capecitabine), adriamycin and paclitaxel using MCF7 and T47D breast cancer cell lines engineered to express doxycycline inducible Y537S-ESR1 mutation. Results: We found that in MCF7 cells the combination of chemotherapy and fulvestrant was synergistic and the synergy was augmented with the induction of the Y537S mutation. In contrast, there was no synergy in T47D cells that harbor a P53 mutation. We confirmed that the synergistic activity of fulvestrant with chemotherapy is dependent on P53 by generating P53 knock-out MCF7 cells using CRISPR-cas9. Additionally, cell cycle and apoptosis analyses showed that the synergistic activity was mainly due to increased effects on G1 arrest rather than apoptosis. Conclusions: Our study indicates that chemotherapy and fulvestrant are synergistic in ER+ breast cancer and the synergy is increased in the presence of the Y537S ESR1 mutation and is dependent on P53 activity. These results support a clinical trial testing the addition of fulvestrant or other novel selective estrogen receptor degraders in patients with metastatic ER+ breast cancer who are starting chemotherapy treatment.
Preliminary study on new mode of Beijing's Desheng Community family doctor's service
Authors: Fengjuan Gao, Yuhui Shi, Peiyu Wang, Zhengzheng Han, Juhong Liu, Zhihong He, Yan Xie
Journal: BMJ (2015)

Since January 2013, Desheng Community in Beijing has constructed a new team mode of forming an expert team of a pharmacist, a nurse assistant and a general practitioner from Beijing University First Hospital. The tasks of each team member were well-defined. The clinic outpatients were registered and lifestyle interventions incorporated into service procedures. For performance evaluations, the relevant indicators were quantized for each team member and team work was appraised directly. After implementing this new service mode, the elder's proportion of preferred community health providers and registration rate increased from 46.02%(434/943), 20.80%(183/880) to 66.89%(604/903), 53.80%(474/881) respectively. And the increases for hypertensives and diabetics were from 55.29%(256/463), 18.22%(80/439) to 69.20%(301/435), 60.94%(259/425)and from 44.91%(238/530), 24.81%(132/532)to 63.20%(256/405), 54.80%(217/396) respectively.


Key words: 
Home care services; Physicians, family; Community health centers
静脉窦血栓形成七例
Authors: 姜春莉, 孙迎男, 朴明淑
Journal: BMJ (2005)

静脉窦血栓形成的临床表现复杂多样,约20%病因不明,误诊率高,死亡率达10%～20%.近年来通过磁共振血管成像(MRV),明显提高了诊断率,改善了预后.现将我科近3年收治的7例患者报告如下。
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.
Authors: Gerald Steven Falchook, Johanna C. Bendell, Susanna Varkey Ulahannan, Shiraj Sen, Rasa Vilimas, Kristina Kriksciukaite, Laura Mei, Goran Jerkovic, Nenad Sarapa, Mark Bilodeau, Jeffrey Bloss, Anish Thomas
Journal: Journal of Clinical Oncology (2020)

3515 Background: PEN-866 is a miniature drug conjugate which links a HSP90 binding small molecule to a SN-38 cytotoxic payload. HSP90 is highly expressed in advanced malignancies. PEN-866 targets and binds to activated tumor HSP90 protein, releases its cytotoxic payload, and results in complete tumor regressions in multiple xenograft models. This first-in-human study assessed safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of PEN-866. Methods: Patients (pts) with progressive, advanced solid malignancies were enrolled in escalating cohorts of 2-9 pts. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of PEN-866 given weekly (3 out of 4 weeks in a 28-day cycle). Results: 30 pts were treated in 8 cohorts (range 30-360 mg flat dosing or 150–200 mg/m 2 BSA-based dosing). As of 9Jan20, the total median/mean exposure was 7.05/12.4 weeks. No dose limiting toxicities (DLTs) occurred in the first 4 cohorts (30-240 mg; 14 pts). In cohort 5 (360 mg), 1 of 3 pts had a DLT of grade (G) 3 transient diarrhea, and 2 other pts had G3 uncomplicated transient neutropenia. A change to BSA-based dosing was instituted for cohort 6 (175 mg/m 2 ), on which no DLTs were observed, although 1 pt experienced G3 uncomplicated transient neutropenia. At 200 mg/m 2 , 2 of 5 pts experienced DLTs (G5 dehydration, G3 fatigue). The MTD and RP2D were determined to be 175 mg/m 2 . The most frequent (≥20% pts) related adverse events were nausea (50%), fatigue (43%), diarrhea (40%), vomiting (27%), and anemia (23%). PK was nonlinear. Plasma exposures increased greater than dose proportionally. Median t 1/2 ~7 h. Cleaved SN38 never exceeded 3% of PEN-866 plasma AUC at all dose levels. Tissue PK confirmed tumor accumulation and retention of both the conjugate and released payload. As of 9Jan20, 26 pts were evaluable for response. 11 pts had stable disease at 8 weeks, of which 7 lasted 12–58 weeks. One pt with anal squamous cell carcinoma achieved a confirmed partial response. Decreased target lesion size was observed in 6 additional pts. Conclusions: PEN-866 was well tolerated and demonstrated preliminary evidence of antitumor activity. PEN-866 will be evaluated in Phase 2a expansion cohorts enrolling multiple solid tumors (NCT03221400). Clinical trial information: NCT03221400 .
Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).
Authors: Kate Ida Lathrop, Virginia G. Kaklamani, Andrew Jacob Brenner, Rong Li, Alia Nazarullah, Sarah Hackman, Courtney Thomas, Jonathan Gelfond, Marisa Rodriguez, Richard Elledge
Journal: Journal of Clinical Oncology (2020)

560 Background: Patients with TNBC breast cancer have inferior treatment outcomes compared to other breast cancer subtypes and targeted therapies are lacking. S-equol is a novel oral Estrogen Receptor (ER) Beta agonist with preclinical data showing suppression of TNBC cellular proliferation. We therefore conducted an early phase window of opportunity trial to evaluate the impact of S-equol on Ki-67 change in patients with TNBC. Methods: This neoadjuvant window trial enrolled 39 patients with confirmed TNBC on diagnostic core needle biopsy. Cohort A (20 patients) received a daily dose of 50 mg daily and Cohort B (19 patients) received a higher dose of 150 mg daily. Paired biopsies were evaluable for 36 patients. Both cohorts were treated for a duration of 10-21 days. Primary outcome was change from pre- to post-treatment Ki-67 evaluated by paired t-test. All tests were 2-sided with a significance level of 0.05. Statistics were conducted within an accountable data analysis process in R (ADAPR). Secondary outcomes included toxicity and correlative biomarkers. Results: The mean (SD) pre-treatment was 68% (21.99) and post-treatment 59% (20.62). The average decrease in Ki-67 was 8% (P = 0.00206, 95% CI -13.46 to -3.26). A Ki-67 decrease of at least 20% from baseline was observed in 28% of the patients. S-equol was well tolerated with the most common toxicities being nausea, constipation, diarrhea, and headache. All toxicities were grade one. Treatment compliance was greater than 95%. Planned correlative studies included RNA-seq. A total of 161 genes are differentially expressed with fold change &gt; = 2 and p value &lt; 0.05. The top genes of the differential expression list include BMP5, S100A7, FABP7, SCGB2A2, CH507-338C24.1, and DUSP1. Gene Set Enrichment Analysis (GSEA) indicates that top enriched gene modules are related to interferon function and immune response, most of which are downregulated in the post-treatment group. Conclusions: S-equol is a novel well tolerated oral ER-Beta agonist with inhibition of proliferation in patients with TNBC as measured by a decrease in Ki-67. RNA-seq data supports potential immune activation during this short period of drug exposure. Future studies aim to evaluate S-equol as an immune activating agent for combination with immunotherapies such as checkpoint inhibitors in TNBC. Clinical trial information: NCT02352025 .
A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index
Authors: 张玉萍, 龚瑶, 曾庆馀, 侯志铎, 肖征宇
Journal: BMJ (2015)

目的
了解小剂量糖皮质激素(GC)治疗强直性脊柱炎(AS)的不良反应，以及对患者骨密度、血糖、血脂和体质指数的影响。


设计
本研究为回顾性观察性队列研究。比较应用激素组和非激素组的不良反应发生率，并比较不同的GC用药时间内的不良反应(分为非GC组、 2年组)。


地点
中国一所三级综合医院30年的风湿科门诊资料。


对象
纳入830例随访半年以上的AS患者，排除既往或现有活动性消化道疾病、高血压、精神疾病、糖尿病、结核或肝炎的患者。中位随访时间为1.6年(范围0.5～15年，共1 801人年)。


结果
小剂量激素组共555例(66.9%)，中位累积GC治疗时间为1.3年(范围0.1～8.5年)。皮肤系统的不良反应，包括痤疮、瘀斑以及皮肤感染为最常见的不良反应，累积发生率为5.4%(平均每1 000人年22.2例)，其次为满月脸(1.6%)，明显体重增加(1.1%)以及严重感染(1.0%)。其余的不良反应发生率均少于1%。GC组别以及GC治疗时间与低骨密度、血脂异常、高血糖和肥胖无相关性(P>0.05)。


结论
长期小剂量GC治疗AS的不良反应发生率低。小剂量GC对骨密度、血脂、血糖以及体质指数无不良影响。
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.
Authors: Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John Paul Leonard, James L. Rubenstein
Journal: Journal of Clinical Oncology (2020)

8042 Background: Optimal consolidative therapy for primary central nervous system lymphoma (PCNSL) is not defined. Avoidance of whole brain radiation may reduce risk of neurotoxicity. Non-radiation consolidative options include myeloablative chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) or non-myeloablative chemotherapy. Methods: This is a randomized phase 2, National Clinical Trials Network study of induction methotrexate (MTX) (8 g/m 2 days 1, 15), temozolomide (TMZ) (150-200 mg/m 2 D7-11), and rituximab (RTX) (C1 D3, 10, 17, 24 and C2 D3, 10) in four 28-day cycles followed by one cycle of cytarabine (ARA-C) (2 g/m 2 BID, D1, 2) (MTRA). Following induction, patients (pts) received consolidation with thiotepa (5 mg/kg BID, D -5, -4) plus carmustine (400 mg/m 2 , day -6) and ASCT (Arm A) or one cycle of ARA-C (2 g/m 2 BID, D1-4) plus infusional etoposide (40 mg/kg over 96h) (Arm B). The primary endpoint was median progression-free survival (PFS), designed to compare consolidation regimens. This report describes the results of the 5 cycles of induction therapy. Results: 113 pts (median age 61 years, range 33-75) were randomized (Arm A: 57, Arm B: 56) across 27 centers. 108 eligible pts who received induction therapy were evaluated. 36 pts (33.3%) did not proceed to consolidation, mainly due to disease progression (17), pt withdrawal (8), or adverse events including death (6). Grade 3 or 4 febrile neutropenia occurred in 12 pts (11.1%) during induction. Dose modifications of MTX were required in 75% of pts and 63.3% of cycles, mainly due to renal adjustments. Dose delays of MTX were required in 52.8% of pts and 22.2% of cycles. Overall response rate (CR, CRu, PR) at the end of induction was 65.7% (95% CI, 56%, 74.6%). Conclusions: While MTRA is feasible and active a significant proportion of pts did not receive consolidation, supporting the need to develop more effective induction strategies. Clinical trial information: NCT01511562 .
中药辅助治疗对卵巢癌术后化疗患者生存质量的影响
Authors: 孔守芳, 孙选, 陈芊, 李旭日, 莫平
Journal: BMJ (2011)

生存质量已广泛应用于癌症和慢性病患者的临床测评,除了可以反映患者的综合状况外,更被用于药物疗效和治疗方案的评价与选择[1].本研究在对卵巢癌术后化疗患者应用中药干预时,使用欧洲癌症研究与质量组织生命质量问卷第三版(QIQ-C30V 3.0)测评中药改善患者生存质量的效果。
心律失常
Authors: 吴东, 刘永太, 陈嘉林
Journal: BMJ (2011)

一、识别快速心律失常的关键:一看QRS波,二看节律 快速心律失常虽然不是社区的常见病,但属于临床急症,伞科医师应有所了解.一种快速简明的鉴别方法,是根据QRS波的宽窄以及节律是否齐整,将快速心律失常分为以下3类:①窄QRs波,节律齐:最常见于窦性心动过速(心电图有正常P波),多有病因,例如感染、贫血、疼痛、缺氧等,治疗以对因为主.老年人和冠心病患者可酌情应用β受体阻滞剂控制心率。
Effect of neuroendocrine component in pancreatic adenocarcinoma on blood levels of steroid hormones.
Authors: Viacheslav A. Aleynov, Elena M. Frantsiyants, Valeria A. Bandovkina, Natalia D. Cheryarina, Vladimir S. Trifanov, Maksim N. Chernyak, Stanislav S. Mezentsev, Fedor N. Grechkin, Tanzila Beksultanovna Katsieva, Oleg I. Kit, Alexander V. Shaposhnikov, Dmitry S. Petrov, Yuriy A. Fomenko
Journal: Journal of Clinical Oncology (2020)

e16695 Background: 90% of pancreatic cancers are adenocarcinomas. Pancreatic neuroendocrine tumors (PNET) are much less common. However, some adenocarcinomas carry a neuroendocrine component and have an effect on the hormonal profile of the body. The purpose of the study was to analyze the content of steroid hormones and ACTH in the blood of patients with pancreatic cancer in dependence on the neuroendocrine component presence. Methods: Standard RIA methods were used to measure blood level of testosterone (T), estradiol (E2), progesterone (P4), cortisol and ACTH in 10 patients with pancreatic adenocarcinoma (PA), 12 patients with PNET and 20 patients with PA with a neuroendocrine component (PA+NEC). The results were compared with the levels in 23 healthy donors. All patients gave voluntary informed consent for the study. Results: Levels of all measured hormones were elevated in the blood of patients with PA: T by 1.8 times, P4 by 4.8 times, E2 by 2.7 times, cortisol by 2 times and ACTH by 2.5 times, compared to donors. In PNET, E2 was 1.5 times (p &lt; 0.05) lower, and T 1.6 times (p &lt; 0.05) higher than in donors. Levels of P4, ACTH and cortisol in PNET were similar to normal values. In PA+NEC, T was decreased by 1.3 times, P4 and ACTH increased by 1.4 and 2.2 times respectively. E2 and cortisol were similar to normal values. Conclusions: The hormonal profiles of patients with PNET and PA differ, except T with blood levels increasing in both tumors. The presence of NEC in PA decreases blood levels of T and normalizes E2 and cortisol.
空腹血糖受损人群临床与代谢指标特征
Authors: 石福彦, 杜群, 田改生, 李子玲, 孙春梅, 李畅蕾, 董智慧, 刘美英
Journal: BMJ (2006)

为探讨诊断切点下调后空腹血糖受损(IFG)人群的临床及代谢指标特征,对糖调节受损(IGR)人群2年自然转归研究中的232例空腹血糖受损及145例正常糖耐量(NGT)者进行研究.空腹血糖受损诊断采用2003年美国糖尿病协会专家委员会建议标准.结果显示空腹血糖受损人群血压、体重指数、腰围、腰臀比、甘油三酯、胆固醇、血尿酸均明显高于正常糖耐量组;空腹血糖受损组胰岛素抵抗指数明显高于正常糖耐量组,而胰岛β细胞功能指数则低于正常糖耐量组.诊断切点下调后的空腹血糖受损人群血压及代谢综合征的指标均高于正常糖耐量组,其高血压、高血脂、肥胖的患病率高于正常糖耐量组,同时空腹血糖受损人群表现出胰岛素抵抗这一代谢综合征的基本病理特征。
Application of LEEP on the dincnosis and treatment of cervical lesions
Authors: 朱鹃, 卞美璐
Journal: BMJ (2011)

近年随着宫颈上皮内瘤变(CIN)发病率的增高和发病年轻化,宫颈锥形切除术(锥切术)得以重视和广泛应用.传统的宫颈锥切术手术范围较大,并发症较多,目前治疗方式不断拓展,包括电刀切除术、宫颈环形电切除术(loop electrosurgical excision procedure,LEEP)、激光锥切、冷冻、激光汽化、电熨疗法等,其中以LEEP应用最广。
Limonoid compounds from <i>Xylocarpus granatum</i> and their anti-cancer activity against esophageal cancer cells.
Authors: Li Jing, Li Feng, Zhiguo Zhou, Shuai Shi, Ruoying Deng, Zhicong Wang, Yibing Liu
Journal: Journal of Clinical Oncology (2020)

e16516 Background: We aimed to study the anti-cancer effects of limonoid compounds that were isolated and purified from Xylocarpus granatum fruits on human esophageal cancer cells. A structure-activity relationship experiment was designed to identify the functional moiety of limonoid compounds identified as being critical for its anti-cancer activity. Methods: Esophageal cancer Eca109 cells were treated with limonoid compounds. Cell proliferation was determined by the MTT assay in vitro and cellular apoptosis by flow cytometry and Western Immunolotting. Results: Four linonoid compounds strongly inhibited the cellular proliferation of Eca109 cells. Xylogranatin C was the strongest inhibitor, whose inhibitory effect was comparable to that of the well-known chemotherapeutic agent, cisplatin. Furthermore, xylogranatin C might induce Eca109 cell apoptosis through joint effects on multiple pathways, including the death receptor and endoplasmic reticulum pathways. Additionally, xylogranatin C suppressed tumor cell proliferation by up-regulating miR-203a expression in Eca109 cells. Conclusions: Inhibitory effects of xylogranatin C were more potent than cisplatin. Xylogranatin C induced Eca109 cellular apoptosis and exerted anti-tumor activity. Xylogranatin C might have induced Eca109 cellular apoptosis via joint effects on multiple pathways, including the death receptor and mitochondria-dependent signaling pathways. Additionally, xylogranatin C suppressed tumor cell proliferation by up-regulating miR-203a expression in Eca109 cells.
Association of postoperative radiotherapy with survival in patients with completely resected pathologic N2 non-small cell lung cancer treated with chemotherapy.
Authors: Yuan Zeng, Wenhua Liang, Jian He
Journal: Journal of Clinical Oncology (2020)

e21008 Background: The current staging system for completely resected pathological N2 non-small-cell lung cancer (NSCLC) treated with chemotherapy is not suitable for predicting those patients most likely to benefit or not from post-operative radiotherapy (PORT). This study aimed to construct a survival prediction model that will enable individualized predictions of the net survival of PORT. Methods: A total of 3094 cases between 2002 and 2014 were extracted from the Surveillance, Epidemiology, and End Results databases. Patient characteristics were included as covariates, and their association for overall survival (OS) with and witout PORT was assessed. Externally validate data of 602 patients were included from China. Results: A total of 3696 patients were included for analysis. Age, gender, examined lymph node, positive lymph node, tumor size, extent of surgery, and visceral pleural invasion were significantly associated with OS, with P &lt; .05. The calibration curve for OS showed great agreement between prediction by survival prediction model and actual observation.In the training cohort, the C-index for OS was 0.619 (95% CI, 0.598-0.641) in the PORT group and 0.627 (95% CI, 0.605-0.648) in the non-PORT group. In the externally validation cohort, the C-index for OS was 0.599 (95% CI, 0.485- 0.713) in the PORT group and 0.595 (95% CI, 0.544-0.646) in non-PORT group. The two survival prediction models were developed based on clinical variables to estimate an individual's net survival gain or not attributable to PORT. We found that PORT could improve OS (HR, 0.861; P = 0.044) for patients with a positive PORT net survival benefit. Conclusions: We established a practical survival prediction model that can be used to make individualized predictions about the expected survival of PORT or without PORT in patients with completely resected pathological N2 NSCLC, treated with chemotherapy.
An update on vitamin D signaling and cancer
Authors: Carsten Carlberg, Alberto Muñoz
Journal: Seminars in Cancer Biology (2020)

A low vitamin D status is associated with an increased risk of various cancers, such as of colon, breast, prostate and hematological cells. The biologically most active vitamin D metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is a high affinity ligand of the transcription factor vitamin D receptor (VDR). 1,25(OH)2D3 induces via VDR changes to the epigenome of healthy and neoplastic cells and in this way influences their transcriptome. Ligand-activated VDR binds to more than 10,000 loci within the human genome and affects the transcription of some 1000 target genes in a large proportion of human tissues and cell types. From the evolutionary perspective, the prime role of vitamin D was probably the control of energy metabolism later shifting to modulate innate and adaptive immunity as well as to regulate calcium and bone homeostasis. Since rapidly growing immune and cancer cells both use the same pathways and genes for controlling their proliferation, differentiation and apoptosis, not surprisingly, vitamin D signaling changes these processes also in neoplastic cells. Thus, anti-cancer effects of vitamin D may derive from managing growth and differentiation in immunity. This review provides an update on the molecular basis of vitamin D signaling, i.e., the effects of 1,25(OH)2D3 on the epigenome and transcriptome, and its relationship to cancer prevention and therapy.
Prevalence of SARS-CoV-2 Among Patients Admitted for Childbirth in Southern Connecticut
Authors: Katherine H. Campbell, Jean M. Tornatore, Kirsten E. Lawrence, Jessica L. Illuzzi, L. Scott Sussman, Heather S. Lipkind, Christian M. Pettker
Journal: JAMA (2020)

Lan Dong, MD; Jinhua Tian, MD; Songming He, MD; Chuchao Zhu, MD; Jian Wang, MD; Chen Liu, MD; Jing Yang, MD